


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/667,208
Filing Date	September 19, 2003
First Named Inventor	Carson, Dennis
Group Art Unit	1614
Examiner Name	Unknown R. Henley

Sheet 1 of 4

Attorney Docket No: 103.032US1

**US PATENT DOCUMENTS**

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
<i>[Signature]</i>	US-3,843,681	10/22/1974	Demerson, C. A., et al.	260	326.14 R	06/01/1971
	US-4,337,760	07/06/1982	Rubin, D.	128	1 R	10/31/1979
	US-5,561,151	10/01/1996	Young, J. W., et al.	514	411	01/04/1995
	US-5,811,558	09/22/1998	Adger, B. M., et al.	548	427	04/11/1995
	US-5,939,455	08/17/1999	Rephaeli, Ada	514	547	03/11/1997
	US-5,955,504	09/21/1999	Wechter, William J., et al.	514	568	03/13/1995
	US-6,066,741	05/23/2000	Vigano, E., et al.	548	432	09/08/1998
	US-6,545,034	04/01/2003	Carson, et al.	514	411	07/23/1999

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T <sup>2</sup>
<i>[Signature]</i>	DE-2226340	03/15/1973	Demerson, Christopher A., et al.	C07D	27/56	Abstract only
	EP-0289262	11/02/1986	Venuti, M. C., et al.	C07C	93/00	
	WO-00/02555	01/20/2000	Nardella, Francis A., et al.	A61K	31/40	
	WO-00/13410	03/09/2000	Monroe, D. A.	H04N	5/76	
	WO-96/28148	09/19/1996	Wechter, William J., et al.	A61K	31/19	
	WO-98/09603	03/12/1998	Wechter, William J., et al.	A61K		
	WO-98/18490	05/07/1998	Clynes, M. M.	A61K	45/06	

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume+issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>[Signature]</i>		ABRAMSON, S. B., et al., "The Mechanisms of Action of Nonsteroidal Antiinflammatory Drugs", <u>Arthritis &amp; Rheumatism</u> , 32 (1), (Jan. 1989), 1-9	
		ALEXANIAN, R., et al., "The Treatment of Multiple Myeloma", <u>The New England Journal of Medicine</u> , 330 (7), (Feb. 17, 1994), 484-489	
		BARLOGIE, B., et al., "Prognostic Factors with High-Dose Melphalan for Refractory Multiple Myeloma.", <u>Blood</u> , 72, (1988), 2015-2019	
		BATAILLE, R., et al., "Multiple Myeloma", <u>New England Journal of Medicine</u> , 336, (1997), 1657-1664	
		BECKER-SCHARFENKAMP, U., et al., "Evaluation of the Stereoselective Metabolism of the Chiral Analgesic Drug Etodolac by High-Performance Liquid Chromatography", <u>Journal of Chromatography</u> , 621 (2), (Nov. 24, 1993), 199-207	
<i>[Signature]</i>		BELLOSILLO, B., et al., "Aspirin and Salicylate Induce Apoptosis and Activation of Caspases in B-Cell Chronic Lymphocytic Leukemia Cells", <u>Blood</u> , 92 (4), (2001) ->	

EXAMINER *[Signature]*


DATE CONSIDERED

6/15/04

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**  
 (Use as many sheets as necessary)



PTO/SB/08A(10-01)  
 Approved for use through 10/31/2002. OM 8 861-0001  
 US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<i>Complete if Known</i>	
Application Number	10/667,208
Filing Date	September 19, 2003
First Named Inventor	Carson, Dennis
Group Art Unit	1614
Examiner Name	Unknown R. HENLEY

Attorney Docket No: 103.032US1

Sheet 2 of 4

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		(Aug. 15, 1998), 1406-1414	
		BERENDES, U., et al., "Simultaneous Determination of the Phase II Metabolites of the Non Steroidal Anti-inflammatory Drug Etodolac in Human Urine", <u>Enantiomer</u> , 1, Abstract Only, Chemical Abstracts, Abstract No. 126:207064q,(1996), 415-422	
		BRENNAN, E., et al., "New Enzymatic and Chemical Approaches to Enantiopure Etodolac", <u>Tetrahedron</u> , 53, (1997), 17769-17780	
		BROCKS, D. R., et al., "Etodolac Clinical Pharmacokinetics", <u>Clinical Pharmacokinetics</u> , 26 (4), (1994), 259-274	
		CARSON, D. A., et al., "Oral Antilymphocyte Activity and Induction of Apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine", <u>Proc. Natl. Acad. Sci. USA</u> , 89 (7), (Apr. 1992), 2970-2974	
		CHINETTI, G., et al., "Activation of Proliferator-activated Receptors alpha and Y Induces Apoptosis of Human Monocyte-derived Macrophages", <u>The Journal of Biological Chemistry</u> , 273 (40), (Oct. 2, 1998), 25573-25580	
		CUNNINGHAM, D., et al., "High-dose Melphalan for Multiple Myeloma: Long-term Follow-up Data", <u>Journal of Clinical Oncology</u> , 12, (1994), 764-768	
		DEMERSON, C. A., et al., "Etodolic Acid and Related Compounds. Chemistry and Antiinflammatory Actions of Some Potent Di- and Trisubstituted 1,3,4,9-Tetrahydropyrano[3,4-b]indole-1-acetic Acids", <u>Journal of Medicinal Chemistry</u> , 19 (3), (1976), 391-395	
		DEMERSON, C. A., et al., "Resolution of Etodolac and Antiinflammatory and Prostaglandin Synthetase Inhibiting Properties of the Enantiomers", <u>J. Med. Chem.</u> , 26 (12), (Dec. 1983), 1778-1780	
		DRACHENBERG, D. F., et al., "Treatment of Prostate Cancer: Watchful Waiting, Radical Prostatectomy, and Cryoablation", <u>Seminars in Surgical Oncology</u> , 18 (1), (Jan/Feb. 2000), 37-44	
		DUFFY, C. P., et al., "Enhancement of Chemotherapeutic Drug Toxicity to Human Tumour Cells In Vitro by a Subset of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)", <u>European Journal of Cancer</u> , 34 (8), (July 1998), 1250-1259	
		HAHNFELD, L. E., et al., "Prostate Cancer", <u>The Medical Clinics of North America - The Aging Male Patient</u> , 83 (5), (Sept. 1999), 1231-1245	
		HAROUSSEAU, J. L., et al., "Double-Intensive Therapy in High-Risk Multiple Myeloma", <u>Blood</u> , 79 (11), (June 1, 1992), 2827-2833	
		KRAJEWSKI, S., et al., "Detection of Multiple Antigens on Western Blots", <u>Analytical Biochemistry</u> , 236 (2), Article No. 0160,(May 1996), 221-228	
		LANDIS, S. H., et al., "Cancer Statistics, 1998", <u>CA Cancer J. Clin.</u> , 48 (1), (1998), 6-29	
		LEE, D. H., "Proteasome Inhibitors: Valuable New Tools For Cell Biologists", <u>Trends in Cell Biology</u> , 8, (October 1998), 397-403	
		LEHMANN, J. M., et al., "Peroxisome Proliferator-activated Receptors alpha and (c) (b) (4) ->	

EXAMINER

DATE CONSIDERED


6/15/04

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)



## Complete if Known

Application Number	10/667,208
Filing Date	September 19, 2003
First Named Inventor	Carson, Dennis
Group Art Unit	1614
Examiner Name	Unknown R. Henley

Sheet 3 of 4

Attorney Docket No: 103.032US1

## OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T*
X		Y Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs", <u>The Journal of Biological Chemistry</u> , 272 (6), (Feb. 7, 1997), 3406-3410	
		LEMAN, EDDY S., et al., "Characterization of the Nuclear Matrix Proteins in a Transgenic Mouse Model for Prostate Cancer", <u>Journal of Cellular Biochemistry</u> , 86, (2002), 203-212	
		LEONI, L. M., et al., "Induction of an Apoptotic Program in Cell-Free Extracts by 2-Chloro-2'-deoxyadenosine 5'-triphosphate and Cytochrome C", <u>PNAS, USA</u> , 95 (16), (Aug. 4, 1998), 9567-9571	
		LOCHMULLER, C. H., et al., "Chromatographic Resolution of Enantiomers -- Selective Review", <u>Journal of Chromatography</u> , 113 (3), (Oct. 22, 1975), 283-302	
		MARTEL, R. R., et al., "Anti-inflammatory and Analgesic Properties of Etodolic Acid in Rats", <u>Canadian Journal of Physiology and Pharmacology</u> , 54 (3), (June 1976), 245-248	
		MOONEY, P. T., et al., "Cell Pathways' Exisulind 'Aptosyn' Demonstrates Potential to Delay Hormone Therapy in Post-Prostatectomy Men at Risk of Prostate Cancer Recurrence", <a href="http://biz.yahoo.com/bw/000501/ga_cell_pa_1.html">http://biz.yahoo.com/bw/000501/ga_cell_pa_1.html</a> , (May 2000), 3 pages	
		NARDELLA, FRANCIS A., et al., "Enhanced Clearance of Leukemic Lymphocytes in B Cell Chronic Lymphocytic Leukemia (CLL) with Etodolac", <u>Arthritis &amp; Rheumatism</u> , 42 (9) Supplement, Abstract No. 41, (Sept. 1999), page S56	
		RICOTE, M., et al., "The Peroxisome Proliferator-Activated Receptor-γ is a Negative Regulator of Macrophage Activation", <u>Nature</u> , 391, (Jan. 1, 1998), 79-82	
		RIEDEL, D. A., et al., "The Epidemiology of Multiple Myeloma", <u>Hematology/Oncology Clinics of North America</u> , Multiple Myeloma, 6 (2), (April 1992), 225-247	
		ROYALL, J. A., et al., "Evaluation of 2',7'-Dichlorofluorescein and Dihydrorhodamine 123 as Fluorescent Probes for Intracellular H2O2 in Cultured Endothelial Cells", <u>Archives of Biochemistry and Biophysics</u> , 302 (2), (May 1, 1993), 348-355	
		SHIFF, S. J., et al., "Nonsteroidal Antiinflammatory Drugs Inhibit the Proliferation of Colon Adenocarcinoma Cells: Effects on Cell Cycle and Apoptosis", <u>Experimental Cell Research</u> , 222, Article No. 0023, (1996), 179-188	
		TANG, D. G., et al., "Target to Apoptosis: A Hopeful Weapon for Prostate Cancer", <u>The Prostate</u> , (1997), 284-293	
		VAN BREEMEN, R. B., et al., "Characterization of Oxygen-Linked Glucuronides by Laser Desorption Mass Spectrometry", <u>Biomed. Mass Spectrom.</u> , 11, Abstract Only, Chemical Abstracts, Abstract No. 101:106777c, (1984), 278-283	
J		VENUTI, M. C., et al., "Synthesis and Biological Evaluation of omega-(N,N,N-trialkylammonium)alkyl Esters and Thioesters of Carboxylic Acid Nonsteroidal (CON <sup>4</sup> )	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)


\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/667,208
Filing Date	September 19, 2003
First Named Inventor	Carson, Dennis
Group Art Unit	1614
Examiner Name	Unknown R. Hawley

Sheet 4 of 4

Attorney Docket No: 103.032US1

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>[Signature]</i>		Antiinflammatory Agents", <u>Pharm. Res.</u> , 6, Abstract Only, Chemical Abstracts, Abstract No. 112:111681y, (1989), 867-873	
<i>[Signature]</i>		WANG, X., et al., "Antipoptotic Action of 1,25-Dihydroxyvitamin D3 Is Associated with Increased Mitochondrial MCL-1 and RAF-1 Proteins and Reduced Release of Cytochrome c", <u>Experimental Cell Research</u> , 235 (1), Article No. EX973667, (1997), 210-217	
<i>[Signature]</i>		WECHTER, W. J., et al., "E-7869 (R-Flurbiprofen) Inhibits Progression of Prostate Cancer in the TRAMP Mouse", <u>Cancer Research</u> , 60, (April 15, 2000), 2203-2208	
<i>[Signature]</i>		WEISS, H. A., et al., "Aspirin, Non-Steroidal Anti-Inflammatory Drugs and Protection from Colorectal Cancer: a Review of the Epidemiological Evidence", <u>Scandinavian Journal of Gastroenterology</u> , 31 (Suppl. 220), (1996), 137-141	
<i>[Signature]</i>		WILEN, S. H., et al., "Strategies In Optical Resolutions", <u>Tetrahedron</u> , 33 (21), Tetrahedron Report Number 38, (1977), 2725-2736	

EXAMINER

DATE CONSIDERED

6/15/04

Substitute Disclosure Statement Form (PTO-1449)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached